Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Intangibles (2021 - 2023)

NovaBay Pharmaceuticals (NBY) has disclosed Intangibles for 3 consecutive years, with $2.2 million as the latest value for Q1 2023.

  • On a quarterly basis, Intangibles changed N/A to $2.2 million in Q1 2023 year-over-year; TTM through Mar 2023 was $2.2 million, a N/A change, with the full-year FY2022 number at $2.3 million, down 56.15% from a year prior.
  • Intangibles was $2.2 million for Q1 2023 at NovaBay Pharmaceuticals, down from $2.3 million in the prior quarter.
  • In the past five years, Intangibles ranged from a high of $5.2 million in Q4 2021 to a low of $2.2 million in Q1 2023.
  • A 3-year average of $3.2 million and a median of $2.3 million in 2022 define the central range for Intangibles.
  • Biggest YoY gain for Intangibles was 56.15% in 2022; the steepest drop was 56.15% in 2022.
  • NovaBay Pharmaceuticals' Intangibles stood at $5.2 million in 2021, then tumbled by 56.15% to $2.3 million in 2022, then fell by 1.67% to $2.2 million in 2023.
  • Per Business Quant, the three most recent readings for NBY's Intangibles are $2.2 million (Q1 2023), $2.3 million (Q4 2022), and $5.2 million (Q4 2021).